<article><a style="color: #000080;" href="http://www.dealstreetasia.com/?s=cadila+healthcare" target="_blank">Cadila Healthcare Ltd</a> has acquired US-based specialty pharmaceutical company Sentynl Therapeutics Inc., engaged in marketing of products in the pain management segment, for an undisclosed amount.</article>

<a style="color: #000080;" href="http://www.dealstreetasia.com/?s=cadila+healthcare" target="_blank">Cadila Healthcare Ltd</a> has acquired US-based specialty pharmaceutical company Sentynl Therapeutics Inc., engaged in marketing of products in the pain management segment, for an undisclosed amount.
This acquisition marks the Ahmedabad-headquartered company’s foray into the $8 billion specialty pain management drug market in the US, as it gains access to Sentynl’s distribution network and large prescriber base, Cadila Healthcare said in a stock exchange filing.
Sentynl, based in San Diego, California, specializes in launching unique products and revitalising marketed brands. The company sources niche and effective products to treat pain and other central nervous system conditions.
Acquisition of Sentynl is in line with Cadila Healthcare’s strategy to enter the specialty drugs market in the US, according to the filing.
“We have always looked at opportunities that can add value to our operations and the acquisition of Sentynl opens up a new business avenue for us. With a strong commitment to offer effective treatment solutions with a focus on pain management, this new development offers us a platform to launch more specialty products in the US market,” Pankaj Patel, chairman and managing director of Cadila Healthcare, said.
The acquisition was solely funded by <a style="color: #000080;" href="http://www.dealstreetasia.com/?s=Bank+of+Tokyo-Mitsubishi+UFJ" target="_blank">Bank of Tokyo-Mitsubishi UFJ</a>, Cadila Healthcare said.
In June 2016, Cadila Healthcare had acquired two abbreviated new drug applications (ANDA) from Teva Pharmaceutical Industries Ltd that were being divested by the Israel-based company as a precondition to its acquisition of Allergan Plc.’s generic business.
The acquired portfolio comprised of an already-commercialized ANDA and one pipeline ANDA, which is a transdermal patch. The estimated market size of the two ANDAs put together was nearly $200 million, the company said.
In the financial year ended March 2016, Cadila Healthcare posted a revenue of Rs9,837.6 crore, the US generics business grew 10% and contributed about 40% to the total revenue.
Also Read:
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/cadila-healthcare-arm-acquires-six-brands-from-msd-pharma-61620/" target="_blank">India: Cadila arm acquires six brands from MSD Pharma</a>
<a style="color: #ff0000;" href="http://www.dealstreetasia.com/stories/zydus-cadila-to-acquire-two-andas-from-teva-pharmaceutical-industries-44858/" target="_blank">India: After Dr Reddy’s, Zydus Cadila to buy two products from Teva Pharma</a>
This article was first in <a style="color: #000080;" href="http://www.livemint.com/Companies/bg89Q0i5fCee7oWylwl32K/Cadila-Healthcare-buys-USbased-Sentynl-Therapeutics.html" target="_blank">Livemint.com</a>

India: Cadila Healthcare buys US-based Sentynl Therapeutics

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

India: Cadila Healthcare buys US-based Sentynl Therapeutics

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief